[A20-67] Romosozumab (osteoporosis) - Addendum to Commission A20-24
Last updated 03.09.2020
Project no.:
A20-67
Commission:
Commission awarded on 28.07.2020 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Muscles, bones and joints
Indication:
| Postmenopausal women with severe osteoporosis at high risk of fracture |
Result of dossier assessment:
| Negative effect for the outcome "cerebrovascular event" qualifies positive effects; now indication of minor added benefit. |
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A20-24 | Romosozumab (osteoporosis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
03.09.2020 A G-BA decision was published.